The role of B cells and autoantibodies in multiple sclerosis

Annals of Neurology

Volumn 47, Issue 6, 2000, Pages 694-706

  Archelos, Juan J ^a   Storch, Maria K ^a   Hartung, Hans Peter ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY;

ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; HUMAN; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL;

ANIMALS; AUTOANTIBODIES; B-LYMPHOCYTES; HUMANS; IMMUNOGLOBULIN G; MODELS, IMMUNOLOGICAL; MULTIPLE SCLEROSIS;

EID: 0034120945     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(200006)47:6<694::AID-ANA2>3.0.CO;2-W     Document Type: Article

References (114)

1. Bornstein MB, Appel SH. The application of tissue culture to the study of experimental "allergic" encephalomyelitis. I. Patterns of demyelination. J Neuropathol Exp Neurol 1961;20: 141-147
2. Kabat EA, Glusman M, Knaub V. Quantitative estimation of the albumin and gamma globulin in normal and pathologic cerebrospinal fluid by immunochemical methods. Am J Med 1948;4:653-662
3. Rajewski K. 1996. Clonal selection and learning in the antibody system. Nature 1996;381:751-758
4. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-252
5. Duchosal MA. B-cell development and differentiation. Semin Hematol 1997;34:2-12
6. + peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 1998;188:1679-1689
7. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-793
8. Morel PA, Oriss TB. Crossregulation between Th1 and Th2 cells. Grit Rev Immunol 1998;18:275-303
9. + T cell responses. Annu Rev Immunol 1997;15:297-322
10. O'Garra A. Cytokines induce the development of functionally heterogenous T helper cell subsets. Immunity 1998;8:275-283
11. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997;18:263-266
12. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995;37:424-435
13. Navikas V, Link H. Cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res 1996;45:322-333
14. Anderson DE, Sharpe AH, Haller DA. The B7-CD28/ CTLA-4 costimulatory pathways in autoimmune disease of the central nervous system. Curr Opin Immunol 1999;11:677-683
15. Benschop RJ, Cambier JC. B cell development: signal transduction by antigen receptors and their surrogates. Curr Opin Immunol 1999;11:143-151
16. Fulcher DA, Basten A. B-cell activation versus tolerance: the central role of immunoglobulin receptor engagement and T-cell help. Intern Rev Immunol 1997;15:33-52
17. Tourtelotte WW. The cerebrospinal fluid in multiple sclerosis. In: Koetsier JC, ed. Handbook of clinical neurology: demyelinating diseases, vol 47. Amsterdam: Elsevier, 1985:79-130
18. Qin Y, Duquette P, Zhang Y, et al. Clonal expansion and somatic hypermutation of VH genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest 1998;102: 1045-1050
19. H4 germline segments in an acute multiple sclerosis brain. Ann Neurol 1998;43:236-243
20. Baranzini SE, Jeong MC, Butunoi C, et al. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol 1999;163:5133-5144
21. Trotter JL, Cross AH. Autoantibodies in demyelinating disease. In: Cook SD, ed. Handbook of multiple sclerosis, 2nd ed. New York: Marcel-Dekker, 1996:187-199
22. Walsh MJ, Murray JM. Dual implication of 2́,3́-cyclic nucleotide 3́ phosphodiesterase as a major autoantigen and C3 complement-binding protein in the pathogenesis of multiple sclerosis, J Clin Invest 1998;101:1923-1931
23. Zanetta JP, Tranchant C, Kuchler-Bopp S, et al. Presence of anti-CSL antibodies in the cerebrospinal fluid of patients: a sensitive and specific test in the diagnosis of multiple sclerosis. J Neuroimmunol 1994;52:175-182
24. Archelos JJ, Trotter J, Previtali S, et al. Isolation and characterization of an oligodendrocyte-precursor-derived B cell epitope in multiple sclerosis. Ann Neurol 1998;43:15-24
25. Gao YL, Raine CS, Brosnan CF. Humoral response to hsp 65 in multiple sclerosis and other neurologic conditions. Neurology 1994;44:941-946
26. Prabhakar S, Kurien E, Gupta RS, et al. Heat shock protein immunoreactivity in CSF: correlation with oligoclonal banding and demyelinating disease. Neurology 1994;44:1644-1648
27. Baig S, Olsson T, Jiang YP, et al. Multiple sclerosis: cells secreting antibodies against myelin-associated glycoprotein are present in CSF. Scand J Immunol 1991;33:73-79
28. Möller JR, Johnson D, Brady RO, et al. Antibodies to myelin-associated glycoprotein (MAG) in the cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 1989;22:55-61
29. Wajgt A, Corny M. CSF antibodies to myelin basic protein and to myelin-associated glycoprotein in multiple sclerosis: evidence of the intrathecal production of antibodies. Acta Neurol Scand 1983;68:337-343
30. Cruz M, Olsson T, Ernerudt J, et al. Immunoblot detection of oligoclonal anti-myelin basic protein IgG antibodies in cerebrospinal fluid in multiple sclerosis. Neurology 1987;37: 1515-1519
31. Warren KG, Catz I, Johnson E, Mielke B. Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis. Ann Neurol 1994;35:280-289
32. García-Merino A, Persson MAA, Ernerudh J, et al. Serum and cerebrospinal fluid antibodies against myelin basic protein and their IgG subclass distribution in multiple sclerosis. J Neurol Neurosurg Psych 1986;49:1066-1070
33. Xiao BG, Linington C, Link H. Antibodies to myelinoligodendrocyte glycoprotein in cerebrospinal fluid from patients wirh multiple sclerosis and controls. J Neuroimmunol 1991;31:91-96
34. Sun J, Link H, Olsson T, et al. T and B cell responses to myelin oligodendrocyte glycoprotein in multiple sclerosis. J Immunol 1991;146:1490-1495
35. Karni A, Bakimer-Kleiner R, Abramsky O, Ben-Nun A. Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis. Arch Neurol 1999;56:311-315
36. Reindl M, Linington C, Brehm U, et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 1999;122:2047-2056
37. Lindert RB, Haase CG, Brehm U, et al. Multiple sclerosis: B-and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain 1999;122:2089-2099
38. Sun J, Olsson T, Wang WZ, et al. Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol 1991;21:1461-1468
39. Colombo K, Banki K, Tatum AH, et al. Comparative analysis of antibody and cell-mediated autoimmunity to transaldolase and myelin basic protein in patients with multiple sclerosis. J Clin Invest 1997;99:1238-1250
40. Bronstein JM, Lallone RL, Seitz RS, et al. A humoral response to oligodendrocyte-specitic protein in MS. Neurology 1999; 53:154-161
41. Pulendran B, van Driel R, Nossal GJV. Immunological tolerance in germinal centres. Immunol Today 1997;18:27-32
42. Inaoki M, Sato S, Weintraub BC, et al. CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes. J Exp Med 1997;186: 1923-1931
43. O'Keefe TL, Williams GT, Batista FD, Neuberger MS. Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 1999;189:1307-1313
44. Henderson A, Calame K. Transcriptional regulation during B cell development. Annu Rev Immunol 1998;16:163-200
45. Elkon KB, Marshak-Rothstein. B cells in systemic autoimmune disease: recent insights from Fas-deficient mice and men. Curr Opin Immunol 1996;8:852-859
46. Silvermans GJ. B-cell superantigens. Immunol Today 1997; 18:379-386
47. Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med 1999;341:2068-2074
48. Gran B, Hemmer B, Vergelli M, et al Molecular mimicry and multiple sclerosis: degenerate T cell recognition and the induction of autoimmunity. Ann Neurol 1999;45:559-567
49. Katz D, Taubenberger JK, Cannella B, et al. Correlation between magnetic resonance imaging and lesion development in chronic active multiple sclerosis. Ann Neurol 1993;34:661-669
50. Storch MK, Lassmann H. Pathology and pathogenesis of demyelinating diseases. Curr Opin Neurol 1997;10:186-192
51. Carroll MC. The role of complement and complement receptors in induction and regulation of immunity. Annu Rev Immunol 1998;16:545-568
52. Esiri MM, Gay D. Immunological and neuropathological significance of the Virchow-Robin space. J Neurol Sci 1990;100: 3-8
53. Prineas JW. Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord. Science 1979;203:1123-1125
54. Van der Goes A, Kortekaas M, Hoekstra K, et al. The role of anti-myelin (auto)-antibodies in the phagocytosis of myelin by macrophages. J Neuroimmunol 1999;101:61-67
55. Hartung HP, Archelos JJ, Zielasek J, et al. Circulating adhesion molecules and inflammatory mediators in demyelination. a review. Neurology 1995;45(Suppl 6):S22-S32
56. Brekke OH, Michaelsen TE, Sandlie I. The structural requirements for complement activation by IgG: does it hinge on the hinge? Immunol Today 1995;16:85-90
57. White KD, Frank MB, Foundling S, Waxman FJ. Effect of immunoglobulin variable region structure on C3b and C4b deposition. Mol Immunol 1996;33:759-768
58. Stefferl A, Brehm U, Storch M, et al. Myelin oligodendrocyte glycoprotein induces experimental autoimmune encephalomyelitis in the "resistant" Brown Norway rat: disease susceptibility is determined by MHC and MHC-linked effects on the B-cell response. J Immunol 1999;163:40-49
59. Whitney KD, McNamara JO. Autoimmunity and neurological disease: antibody modulation of synaptic transmission. Annu Rev Neurosci 1999;22:175-195
60. Lassmann H, Wekerle H. Experimental models of multiple sclerosis. In: Compston A, Ebers G, Lassmann H, et al, eds. McAlpine's multiple sclerosis. 3rd ed. London: Churchill Livingstone, 1998:409-433
61. Brosnan CF, Raine CR. Mechanisms of immune injury in multiple sclerosis. Brain Pathol 1996;6:243-257
62. Lucchinetti C, Brück W, Parisi J, et al. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions: a study of 113 cases. Brain 1999;122:2279-2295
63. Guseo A, Jellinger K. The significance of perivascular infiltrations in multiple sclerosis. J Neurol 1975;211:51-60
64. Esiri MM. Immunoglobulin-containing cells in multiple sclerosis plaques. Lancet 1977;2:478-480
65. Prineas JW, Wright RG. Macrophages, lymphocytes and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest 1978;38:409-421
66. Ozawa K, Suchanek G, Breitschopf H, et al. Patterns of oligodendroglia pathology in multiple sclerosis. Brain 1994;117: 1311-1322
67. Grundke-Iqbal I, Bornstein MB. Multiple sclerosis: serum gamma globulin and demyelination in culture. Neurology 1980;30:749-754
68. Wucherpfennig K, Catz I, Hausmann S, et al. Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes. J Clin Invest 1997;100:1114-1122
69. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999;5:170-175
70. Raine CS, Cannella B, Hauser SL, Genain CP. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann Neurol 1999;46:144-160
71. Prineas JW, Graham JS. Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann Neurol 1981;10:149-158
72. Woyciechowska JL, Brzosko WJ. Immunofluorescence study of brain plaques front two patients with multiple sclerosis. Neurology 1977;27:620-622
73. Lumsden CE. The immunogenesis of the multiple sclerosis plaque. Brain Res 1971;28:365-390
74. Gay D, Esiri M. Blood-brain harrier damage in acute multiple sclerosis plaques: an immunocytochemical study. Brain 1991; 114:557-572
75. Gay FW, Drye TJ, Dick GWA, Esiri MM. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis: identification and characterization of the primary demyelinating lesion. Brain 1997;120:1461-1483
76. Scolding NJ, Morgan BP, Houston WA, et al. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature 1989;339:620-622
77. Storch MK, Piddlesden S, Haltia M, et al. Multiple sclerosis: in situ evidence for antibody and complement mediated demyelination. Ann Neurol 1998;43:465-471
78. Lucchinetti CF, Rodriguez M. The controversy surrounding the pathogenesis of the multiple sclerosis lesion. Mayo Clin Proc 1997;72:665-678
79. Storch MK, Stefferl A, Brehm U, et al. Autoimmunity to myelin oligodendrocyte glycoprotein (MOG) in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998; 8:681-694
80. Lassmann H, Brunner C, Bradl M, Linington C. Experimental allergic encephalomyelitis: the balance between encephalitogenic T lymphocytes and demyelinating antibodies determines size and structure of demyelinated lesions. Acta Neuropathol 1988;75:566-576
81. Linington C, Bradl M, Lassmann H, et al. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/ oligodendrocyte glycoprotein. Am J Pathol 1988;130:443-454
82. Piddlesden SJ, Lassmann H, Zimprich F, et al. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol 1993;143:555-564
83. Bernard CCA, Johns TG, Slavin SAJ, et al. Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. J Mol Med 1997;75:77-88
84. Brunner C, Lassmann H, Waehnelt TV, et al. Differential ultrastructural localization of myelin basic protein, myelin/ oligodendroglia glycoprotein and 2́, 3́-cyclic nucleotide 3́-phosphodiesterase in the CNS of adult rats. J Neurochem 1989;52:296-304
85. Weissert R, Wallstrom E, Storch MK, et al. MHC haplotypedependent regulation of MOG-induced EAE in rats. J Clin Invest 1998;102:1265-1273
86. Lyons JA, San M, Happ MP, Cross AH. B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur J Immunol 1999;29:3432-3439
87. Litzenburger T, Fässler R, Bauer J, et al. B lymphocytes producing demyelinating autoantibodies: development and function in gene-targeted transgenic mice. J Exp Med 1998;188: 169-180
88. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46:878-886
89. Asakura K, Miller DJ, Pease LR, Rodriguez M. Targeting of IgMkappa antibodies to oligodendrocytes promotes CNS remyelination. J Neurosci 1998;18:7700-7708
90. + B lymphocytes. Annu Rev Immunol 1989;7:513-535
91. Mix E, Olsson T, Correale J, et al. B cells expressing CD5 are increased in cerebrospinal fluid of patients with multiples sclerosis. Clin Exp Immunol 1990;79:21-27
92. Hodgkin PD, Basten A. B cell activation, tolerance and antigen-presenting function. Curr Opin Immunol 1995;7: 121-129
93. Gerritse K, Laman JD, Noelle RJ, et al. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1996;93:2409-2504
94. Vanderlugt CT, Begolka WS, Neville KL, et al. The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Immunol Rev 1998;164:63-72
95. Tuohy VK, Yu M, Weinstock-Guttman B, Kinkel RP. Diversity and plasticity of self recognition during the development of multiple sclerosis. J Clin Invest 1997;99:1682-1690
96. Rudick RA, Cookfair DL, Simonian NA, et al. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNβ-1a) for relapsing multiple sclerosis. J Neuroimmunol 1999;93: 8-14
97. McHeyzer-Williams MG, Ahmed R. B cell memory and the long-lived plasma cell. Curr Opin Immunol 1999;11:172-179
98. Pistoia V. Production of cytokines by human B cells in health and disease. Immunol Today 1997;18:343-350
99. Massaro AR, Tonali P. Cerebrospinal fluid markers in multiple sclerosis: an overview. Multiple Sclerosis 1998;4:1-4
100. Ulvestad E, Williams K, Vedeler C, et al. Reactive microglia in multiple sclerosis lesions have an increased expression of receptors for the Fc part of IgG. J Neurol Sci 1994;121:125-131
101. Morgan BP, Gasque P. Expression of complement in the brain: role in health and disease. Immunol Today 1996;17: 461-466
102. Sørensen TL, Tani M, Jensen J, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999;103: 807-815
103. Harling-Berg CJ, Park JT, Knopf PM. Role of the cervical lymphatics in the Th2-type hierarchy of CNS immune regulation. J Neuroimmunol 1999;101:111-127
104. Stott DI, Hiepe F, Hummel M, et al. Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. J Clin Invest 1998;102:938-946
105. Luxton RW, Zeman A, Holzel H, et al. Affinity of antigen-specific IgG distinguishes multiple sclerosis from encephalitis. J Neurol Sci 1995;132:11-19
106. Walsh MJ, Tourtelotte WW. Temporal invariance and clonal uniformity of brain and CSF IgG, IgA, and IgM in multiple sclerosis. J Exp Med 1986;163:41-53
107. Kerschensteiner M, Gallmeier E, Behrens L, et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 1999;189: 865-870
108. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997;120: 393-399
109. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338:278-285
110. Lucchinetti CF, Brück W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 1996;6:259-274
111. Lucchinetti C, Brück W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717
112. Howard-LM, Miga-AJ, Vanderlugt CE, et al. Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J Clin Invest 1999;103:281-290
113. Genain CP, Abel K, Belmar N, et al. Late complications of immune deviation therapy in a non-human primate. Science 1996;274:2054-2057
114. Liu J, Manne MW, Won G, et al. TNF is a potent antiinflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998;4:78-83